Evaluation of MuLtimodal and Non-invasive SPINa Bifida Neurovessels During Prospective Follow-up

Launched by RENNES UNIVERSITY HOSPITAL · Sep 14, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how certain substances in the urine, called biomarkers, can help predict whether patients with spina bifida are at risk of kidney damage. The study focuses on two specific biomarkers, TIMP-2 and MMP-2, which may indicate how well the kidneys are functioning. By measuring these biomarkers during routine tests, researchers hope to find out if they can identify early signs of potential problems in the upper urinary tract, which includes the kidneys.

To participate in the study, individuals must have spina bifida and be receiving care at a specialized center for this condition. They also need to give written consent and be part of a social security program. Participants will have their biomarkers tested during a standard urodynamic assessment, which is a test to check how well the bladder and urethra are working. The study is currently recruiting participants of all ages, and it's a chance for patients to contribute to important research that may improve care for others with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Spina patients consulted as part of the multidisciplinary consultation of the spina bifida rare disease reference centre;
• • Written consent to participate in the research.
• • Compulsory membership of a social security scheme
• Exclusion Criteria:
• • Patients with a non-continuous trans ileal urinary diversion ;
• • Patients with enterocystoplasty;
• • Untreated bacteriuria at the time of urodynamic assessment and urine sample collection;
• • History of urinary tract tumour;
• • History of histologically proven interstitial cystitis;
• • Persons under legal protection (safeguard of justice, curatorship, guardianship);
• • Persons deprived of their liberty.
• • Women claiming to be pregnant